Qd Solutions
Qd Solutions is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HRNMIBC)
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study was conducted in eight countries and enrolled 215 participants overall.
- The adolescent expansion cohort intended to enroll 5 to 10 participants, but only one adolescent was enrolled before study termination.
- The population was expanded in December 2024 to include matched related donors to enhance enrollment rates.
- Planned haploidentical donors and planned abatacept prophylaxis were excluded to maintain population homogeneity and avoid impact on the primary efficacy analysis.
- Home-health visits were added as an alternative to some in-clinic treatment-phase visits at some sites to reduce participant burden.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Subjects with Active Psoriatic Arthritis Axial Disease
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
C5041010 (APD334-207) An Open Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis
Sponsor Arena Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1).
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN).
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis.
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor α Agent
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
OptIMMize-1: A Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease.
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Qd Solutions?
The 2026-10-09 snapshot links Qd Solutions to 16 distinct CTIS trials. Recorded services include Recruitment materials, Branding/creative/logo, Recruitment materials, Print, Branding/creative/logo, recruitment materials, print and production, development of patient facing materials, among 17 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Qd Solutions?
The most frequently recorded therapeutic areas are Immunology, Rheumatology, Blood Disorders, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Qd Solutions conducted?
The linked trials record locations in 19 countries, including Spain, Germany, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Qd Solutions delivered services.
What can this page tell me about Qd Solutions's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Qd Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Qd Solutions Inc.